Neumora Therapeutics reported cash from operations of -$39.53M and free cash flow of -$39.53M for the quarter ended Jun 2026, up 24.6% year over year. This cash flow statement covers 16 quarters of results from Sep 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||
| Net Income | -29.20M | -28.43M | -38.69M | -38.54M | -53.03M | -108.46M | -53.72M | -58.70M | -72.55M | -58.82M | -67.99M | -52.73M | -56.76M | -9.60M | -53.46M | -43.08M |
| Share-based Compensation | 2.10M | 3.36M | 2.19M | 2.54M | 13.65M | 6.05M | 15.13M | 14.63M | 14.17M | 9.90M | 23.64M | 23.45M | 23.37M | 7.41M | 32.45M | 30.83M |
| Gains from Investment Securities | -0.30M | |||||||||||||||
| Asset Writedowns and Impairment | 0.22M | |||||||||||||||
| Cash from Operations | -30.37M | -33.04M | -31.02M | -47.77M | -51.44M | -42.95M | -56.16M | -33.48M | -50.34M | -59.45M | -52.40M | -46.63M | -47.95M | -46.40M | -39.53M | |
| Depreciation, Depletion & Amortization | ||||||||||||||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.15M | 0.16M | 0.17M | 0.17M | 0.20M | 0.16M | 0.16M | 0.16M | 0.16M | 0.16M | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M | |
| Change in Working Capital | ||||||||||||||||
| Change in Account Payables | -3.11M | -6.01M | 7.04M | 0.31M | -1.91M | 1.16M | -0.41M | 5.03M | -2.90M | -2.25M | -0.41M | -0.10M | 2.83M | 1.68M | -0.91M | |
| Change in Accured Expenses | 7.03M | -0.74M | 3.12M | 6.26M | -2.16M | -4.11M | 1.94M | 7.58M | 1.83M | 1.68M | -6.33M | 4.87M | 3.98M | -4.02M | -1.44M | |
| Other Working Capital Changes | 2.07M | -7.86M | 4.24M | 6.89M | 8.13M | -7.35M | 9.74M | -17.69M | -0.60M | -0.97M | -0.91M | 0.04M | 4.60M | -1.64M | 1.51M | |
| Investing Activities | ||||||||||||||||
| Capital Expenditures | 0.02M | 0.04M | 0.04M | 0.04M | ||||||||||||
| Sales of Property, Plant and Equipment | 0.08M | 0.09M | 0.05M | 0.07M | ||||||||||||
| Change in Acquisitions & Divestments | 40.09M | 44.34M | 38.38M | 36.58M | ||||||||||||
| Cash from Investing Activities | -8.03M | 2.82M | 24.08M | 23.82M | 13.68M | -150.00M | 21.25M | 156.99M | -98.80M | 44.16M | 30.40M | 51.32M | 42.65M | 0.07M | ||
| Financing Activities | ||||||||||||||||
| Other financing activities | 0.04M | 0.60M | 0.40M | 231.56M | 1.84M | 2.65M | 1.76M | 1.23M | 0.06M | 0.22M | ||||||
| Debt Issuance and Repayment | ||||||||||||||||
| Long-Term Debt Issuances | -0.14M | 38.90M | ||||||||||||||
| Change in Capital Stock | ||||||||||||||||
| Net Shares Issued and Repurchased | 0.34M | 8.05M | 2.84M | 3.71M | 11.99M | 13.88M | 10.04M | |||||||||
| Net Equity Issued and Repurchased | 24.97M | |||||||||||||||
| Misc. | ||||||||||||||||
| Cash from Financing Activities | 26.83M | 0.10M | 0.29M | 232.02M | -0.48M | 1.84M | 2.65M | 1.53M | 15.57M | 18.46M | -0.14M | 58.77M | 10.88M | 9.29M | ||
| Change in Cash | -11.56M | -30.12M | -6.65M | 208.07M | -38.25M | -191.11M | -32.25M | 125.04M | -133.57M | -15.29M | -3.55M | 4.55M | 53.46M | -35.46M | -30.24M | |
| Free Cash Flow | -30.39M | -33.08M | -31.02M | -47.81M | -51.49M | -42.95M | -56.16M | -33.48M | -50.34M | -59.45M | -52.40M | -46.63M | -47.95M | -46.40M | -39.53M | |
| Net Cash Flow | -11.56M | -30.12M | -6.65M | 208.07M | -38.25M | -191.11M | -32.25M | 125.04M | -133.57M | -15.29M | -3.55M | 4.55M | 53.46M | -35.46M | -30.24M |